Concomitant diabetes with atrial fibrillation and anticoagulation management considerations

Reinhold Kreutz, A John Camm, Peter Rossing


Atrial fibrillation is a highly prevalent cardiac arrhythmia. It is associated with numerous co mobilities. Approximately 30% of diabetic patients have atrial fibrillation and 15% of atrial fibrillation regulation patients have diabetes mellitus. Diabetes increases the likelihood of the development of atrial fibrillation and contributes to the high risk of thromboembolism seen in patients with both diabetes and atrial fibrillation. Chronic kidney disease is often a consequence of diabetes and presents an additional challenge to the management of patients with both atrial fibrillation and diabetes. All non-vitamin K oral anticoagulants are partially eliminated via the kidney and must be carefully prescribed according to strict dosing schedules to avoid anticoagulation overdose. However, NOACs have the advantage of being associated with less progressive impairment of renal function compared with vitamin K antagonist therapy in both diabetics and non-diabetics. Otherwise, diabetic patients benefit from NOAC therapy as opposed to vitamin K antagonists to a similar extent as patients without diabetes. This review deals with anticoagulation treatment in patients with fibrillation and diabetes mellitus, often complicated by progressive renal impairment.

TidsskriftEuropean heart journal supplements : journal of the European Society of Cardiology
Udgave nummerSuppl O
Sider (fra-til)O78-O86
StatusUdgivet - dec. 2020


Dyk ned i forskningsemnerne om 'Concomitant diabetes with atrial fibrillation and anticoagulation management considerations'. Sammen danner de et unikt fingeraftryk.